Trial Profile
A trial to compare two-year experience of fingolimod(FTY) and dimethyl fumarate(DMF) including discontinuation rates, efficacy, and tolerability in the treatment of multiple sclerosis patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 May 2016
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary) ; Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 02 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology